A5039672668- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Bone health and treatments
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Inflammatory Biomarkers in Disease Prognosis
- Allergic Rhinitis and Sensitization
- Central Venous Catheters and Hemodialysis
- Cancer Genomics and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Melanoma and MAPK Pathways
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Atrial Fibrillation Management and Outcomes
Fondazione IRCCS Istituto Nazionale dei Tumori
2020-2023
Ospedale Papa Giovanni XXIII
2020-2021
Palmetto Hematology Oncology
2020
Background Obesity is a risk factor for malignancy; however, its prognostic role in patients with metastatic melanoma controversial. We aim to investigate the of body mass index (BMI) receiving mitogen-activated pathway kinase inhibitors (MAPKi), immune checkpoint (ICIs) alone or their sequence. Methods Data on ≥1 line systemic treatment were retrieved from prospectively collected databases. Progression-free survival (PFS) and overall (OS) analyzed by means multivariable stratified Cox...
Mucosal melanoma is a rare disease epidemiologically and molecularly distinct from cutaneous developing melanocytes located in mucosal membranes. Little known about its therapy. In this paper, we aimed to evaluate the results of immunotherapy radiotherapy group patients with advanced melanoma, based on experience five high-volume centers Poland Italy. There were 82 (53 female, 29 male) included retrospective study. The median age was 67.5 (IQR: 57.25–75.75). All received anti-PD1 or...
Background The presence of ulceration has been recognized as an adverse prognostic factor in primary cutaneous melanoma (PCM). Objectives To investigate whether the extent (EoU) predicts relapse-free survival (RFS) and overall (OS) PCM. Materials methods We retrieved data for 477 patients with ulcerated PCM from databases Italian Melanoma Intergroup. Univariate multivariable Cox proportional hazard models were used to assess independent impact EoU. Results A significant interaction emerged...
Abstract Introduction In advanced Non-Small Cell Lung Cancer (aNSCLC), Programmed Death Ligand 1 (PD-L1) remains the only used biomarker to candidate patients (pts) immunotherapy (IO) even if its predictive accuracy is not satisfactory. Indeed, given complex dynamics underlying cross-talk between tumor and microenvironment, it unlikely that a single could be able profile prediction with high precision. Artificial Intelligence (AI) machine learning (ML) are techniques analyze interpret big...
Abstract Background: HPD has been described in 14-26% of NSCLC pts upon single agent ICI and correlates with poor survival. Currently, occurrence not explored ICI-PCT biomarkers are lacking. Although high circulating neutrophils (Ns) correlated pts, the role specific Ns subsets is unknown. Methods: treated 1st line as or combination PCT were assessed for Ns' phenotype. Tumor response was evaluated by RECIST 1.1. required 3 assessment (2 before ICI, 1 ICI) defined delta tumor growth rate...